ATE269291T1 - Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren - Google Patents

Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren

Info

Publication number
ATE269291T1
ATE269291T1 AT01926670T AT01926670T ATE269291T1 AT E269291 T1 ATE269291 T1 AT E269291T1 AT 01926670 T AT01926670 T AT 01926670T AT 01926670 T AT01926670 T AT 01926670T AT E269291 T1 ATE269291 T1 AT E269291T1
Authority
AT
Austria
Prior art keywords
estrogen receptor
receptor modulators
selective estrogen
salt form
special salt
Prior art date
Application number
AT01926670T
Other languages
English (en)
Inventor
Gary A Cain
Reginald O Cann
Christopher A Teleha
Denette K Murphy
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE269291T1 publication Critical patent/ATE269291T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT01926670T 2000-04-05 2001-04-05 Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren ATE269291T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19458000P 2000-04-05 2000-04-05
PCT/US2001/011169 WO2001077055A2 (en) 2000-04-05 2001-04-05 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
ATE269291T1 true ATE269291T1 (de) 2004-07-15

Family

ID=22718126

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926670T ATE269291T1 (de) 2000-04-05 2001-04-05 Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren

Country Status (12)

Country Link
US (1) US6417394B2 (de)
EP (1) EP1268387B1 (de)
JP (1) JP2004507452A (de)
AT (1) ATE269291T1 (de)
AU (2) AU5319101A (de)
CA (1) CA2403263A1 (de)
DE (1) DE60103867T2 (de)
DK (1) DK1268387T3 (de)
ES (1) ES2222988T3 (de)
PT (1) PT1268387E (de)
TR (1) TR200401601T4 (de)
WO (1) WO2001077055A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417169A2 (de) 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selektive östrogenrezeptormodulatoren
EP1692127B1 (de) 2003-10-08 2008-07-02 Smithkline Beecham Corporation Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
US7196119B2 (en) * 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1951217A4 (de) * 2005-11-22 2009-08-12 Smithkline Beecham Corp Chemische verbindungen
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
CN1275911A (zh) * 1997-08-15 2000-12-06 杜克大学 一种预防或治疗雌激素依赖性疾病及失调的方法

Also Published As

Publication number Publication date
DE60103867T2 (de) 2005-06-30
TR200401601T4 (tr) 2004-08-23
DK1268387T3 (da) 2004-10-18
EP1268387A2 (de) 2003-01-02
EP1268387B1 (de) 2004-06-16
ES2222988T3 (es) 2005-02-16
AU5319101A (en) 2001-10-23
JP2004507452A (ja) 2004-03-11
US20020004496A1 (en) 2002-01-10
DE60103867D1 (de) 2004-07-22
WO2001077055A2 (en) 2001-10-18
CA2403263A1 (en) 2001-10-18
WO2001077055A3 (en) 2002-05-30
US6417394B2 (en) 2002-07-09
AU2001253191B2 (en) 2006-03-02
PT1268387E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
DE69935335D1 (de) Pyrazole als modulatoren des östrogenrezeptors
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
DE69929345D1 (de) Subtituierte isoxazole derivate als estrogen rezeptor modulatore
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
AU2001231710A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
MXPA03001982A (es) Amino-aza-cicloalcanos sustituidos utiles contra la malaria.
WO2003016270A3 (en) Selective estrogen receptor modulators
AU7743001A (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DZ3482A1 (fr) Secretagogues de l'hormone de croissance
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
BR9710255A (pt) Método para o tratamento de cáncer composto de retinóide de adamantila composição farmacéutica ou cosmética de matéria método de tratamento ou de prevenção e método para controlar
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
ATE241641T1 (de) Betulinsäure derivate zur behandlung von neuroektodermalen tumoren
MXPA01008347A (es) Compuestos quimicos.
DE60103867D1 (de) Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren
SE9702483D0 (sv) New compound
DE60105785D1 (de) Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
AP2002002641A0 (en) Estrogen agonist metabolites.
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268387

Country of ref document: EP

REN Ceased due to non-payment of the annual fee